AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Health and Financial Benefits Overview
Contact
Toggle
Overview
Imsidolimab
Rosnilimab
ANB032
Partnerships
Pipeline
DEVELOPMENT STAGE & ANTICIPATED MILESTONES
THERAPEUTIC
INDICATION
ANTIBODY
PROGRAM
LEAD OPTIMIZATION
IND-ENABLING
PHASE 1
PHASE 2
PHASE 3
ANB032: Anti-BTLA Agonist
Inflammatory Diseases
Phase 1 Top-Line
Data Anounced
April 2022
IND Filing of Phase 2 Trial
in Q4 2022
Rosnilimab (ANB030):
Anti-PD-1 Agonist
Alopecia Areata
Phase 1 Top-Line
Data Anounced
Nov 2021
AZURE: Top-Line Data Anticipated Q1 2023
Imsidolimab (ANB019):
Anti-IL-36R
Generalized Pustular
Psoriasis
Phase 1 Data
Presented at
EAACI 2018
ANB033: Antagonist mAb
Inflammatory Diseases
Phase 1 Top-Line
Data Anounced
April 2022
IND Filing H1 2024
GALLOP: Phase 2 Data Presented At
EADV Congress on October 2nd 2021
Top-Line Data
Anticipated Q4 2023